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This randomized phase II trial compared panitumumab plus fluorouracil, leucov-
orin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second-line
chemotherapy for wild-type (WT) KRAS exon 2 metastatic colorectal cancer
(mCRC) and to explore the values of oncogenes in circulating tumor DNA (ctDNA)
and serum proteins as predictive biomarkers. Patients with WT KRAS exon 2
mCRC refractory to first-line chemotherapy containing oxaliplatin and beva-
cizumab were randomly assigned to panitumumab plus FOLFIRI or bevacizumab
plus FOLFIRI. Of 121 randomly assigned patients, 117 were eligible. Median over-
all survival (OS) for panitumumab plus FOLFIRI and bevacizumab plus FOLFIRI
were 16.2 and 13.4 months [hazard ratio (HR), 1.16; 95% CI, 0.76–1.77], respec-
tively. Progression-free survival (PFS) was also similar (HR, 1.14; 95% CI, 0.78–
1.66). KRAS, NRAS, and BRAF status using ctDNA was successfully examined in
109 patients, and mutations were identified in 19 patients (17.4%). Panitumumab
plus FOLFIRI showed favorable survival compared with bevacizumab plus FOLFIRI
in WT patients and unfavorable survival in those with mutations (P for interac-
tion = 0.026 in OS and 0.054 in PFS). OS with bevacizumab plus FOLFIRI was bet-
ter than panitumumab plus FOLFIRI in patients with high serum vascular
endothelial growth factor-A (VEGF-A) levels and worse in those with low levels
(P for interaction = 0.016). Second-line FOLFIRI plus panitumumab and FOLFIRI
plus bevacizumab showed a similar efficacy in patients with WT KRAS exon 2
mCRC. RAS and BRAF mutation in ctDNA could be a negative predictive marker
for panitumumab.
M onoclonal antibodies against both vascular endothelialgrowth factor (VEGF) and epidermal growth factor
receptor (EGFR) improve overall survival (OS) and progres-
sion-free survival (PFS) in patients with metastatic colorectal
cancer (mCRC).(1–3) These antibodies are commonly used as
first- or second-line chemotherapy in combination with back-
bone standard cytotoxic chemotherapy including fluorouracil
and leucovorin with either oxaliplatin (FOLFOX) or irinotecan
(FOLFIRI).(4) Continuous blockade of tumor angiogenesis with
bevacizumab, a monoclonal antibody to VEGF-A, was shown
to be superior to chemotherapy alone in patients who failed
first-line treatment containing bevacizumab.(5) Meanwhile, pan-
itumumab, a fully human monoclonal antibody was also effec-
tive in second-line as combination with FOLFIRI for patients
without mutations in codons 12 and 13 of KRAS exon 2.(3)
Recent reports indicated that less frequent mutations in KRAS,
other than exon 2, and NRAS were also negative predictive
markers for efficacy of anti-EGFR therapies.(6–9)
Although several randomized trials compared bevacizumab
with anti-EGFR monoclonal antibodies in combination with
FOLFIRI or FOLFOX for wild-type (WT) KRAS exon 2
mCRC, no definitive results have yet been reported to establish
a standard sequence for these treatments.(8–11) Thus, establish-
ment of biomarkers is warranted for optimal selection of
patients into treatments and improved overall outcomes. Many
of biomarkers clinically available at present require tumor
samples such as archival tissues. While it has been reported
that biomarker status may change during the treatment course,
it is rather difficult to obtain tumor samples repeatedly espe-
cially for the second or later line treatment. Nowadays, utility
of serum or plasma samples, which can be assessed in a timely
manner, has been investigated such as mutational status of
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tumor oncogenes(12–14) and protein biomarkers including
VEGF-A and human EGFR (HER) family ligands.(15–18) How-
ever, there are few reports on oncogenes detected by circulat-
ing tumor DNA (ctDNA), so-called liquid biopsy, and on
blood biomarkers to distinguish efficacies of VEGF- and
EGFR-targeted therapies in randomized trials of mCRC.
Here, we report the results of a multi-center, open-label, ran-
domized phase II study to compare FOLFIRI plus panitu-
mumab with FOLFIRI plus bevacizumab as second-line
chemotherapy in patients with WT KRAS exon 2 mCRC, with
comprehensive circulating biomarker analysis.
Materials and Methods
Patients. Prior to enrollment in the study, patients had to ful-
fill the following criteria: (i) histopathologically proven unre-
sectable distant metastatic or locally advanced colorectal
adenocarcinoma; (ii) presence of radiographically confirmed or
clinically diagnosed disease progression during or within
3 months after the last dose of first-line chemotherapy
containing fluoropyrimidine, oxaliplatin, and bevacizumab;
(iii) confirmation of WT KRAS exon 2 (codon 12 or 13) using
paraffin-embedded tumor tissue by a validated test method.
KRAS testing conducted previously or during screening period
by local or central laboratory was accepted; (iv) Eastern Coop-
erative Oncology Group performance status (PS) 0–2; (v) age
of 20 years or older; (vi) presence of measurable or non-mea-
surable disease by Response Evaluation Criteria In Solid
Tumor (RECIST) version 1.1; (vii) adequate organ function
(supplementary material, available at online). All patients pro-
vided written informed consent. This study was approved by
the institutional ethics committees of each institution and was
registered at the University Hospital Medical Information
Network (UMIN) Clinical Trials Registry (protocol ID
UMIN000005216).
Treatment schedule and assessment. Patients were random-
ized in a 1:1 ratio to receive either panitumumab at 6 mg/kg
with FOLFIRI once every 2 weeks or bevacizumab at 5 mg/kg
with FOLFIRI every 2 weeks in one cycle. Randomization
was stratified according to institutions and three groups by
K€ohne prognostic index.(19) Treatment was discontinued upon
disease progression, occurrence of unacceptable severe toxic-
ity, or patient request. Radiologic tumor evaluations were
repeated every 8 weeks during the first year and every
12 weeks thereafter by each investigator according to RECIST
version 1.1. Adverse events (AEs) were graded using the Com-
mon Terminology Criteria for Adverse Events version 4.0.
Extended RAS and BRAF mutation analysis using next-genera-
tion sequencing with ctDNA. Patients who provided written
informed consent for biomarker research were included in bio-
marker analysis. Serum samples were collected before the
study treatment. Total nucleic acid content was purified from
0.5 to 1.0 mL serum using QIAamp Circulating Nucleic Acid
kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. The sensitivity assays were performed with geno-
mic DNA extracted from cultured cell lines and healthy human
blood samples as described previously.(20)
Mutant alleles of KRAS and NRAS exon 2 (codons 12 and
13), exon 3 (codons 59, 61,117 and 146), and BRAF exon 15
(codon 600) were assessed.(20,21) Multiplex polymerase chain
reaction (PCR) containing pooled primers for KRAS, NRAS,
and BRAF was performed with the Complete PCR Reagent set
(Sequenom, Japan), followed by the preparation of a barcoded
DNA library using the Ion Plus Fragment Library kit (Thermo
Fisher Scientific, Japan) and IonXpress barcode adaptors
(Thermo Fisher Scientific, Japan). Quantified DNA libraries
were pooled and sequenced using the Ion Proton sequencer.
DNA sequencing data were accessed through the Torrent Suite
v.4.4 (Life Technologies, Carlsbad, CA, USA) software pro-
gram. The Poisson distribution model was used to determine
the presence of mutant alleles. The Poisson coefficient as a
cutoff value was set at average error rate plus 7 standard devi-
ations calculated from normal DNA. The significance level of
error rate was set at 2 9 105.
Serum protein analysis. The following serum proteins were
analyzed: heregulin, hepatocyte growth factor (HGF), extracel-
lular domain of HER type 2 (HER2), amphiregulin,
betacellulin, EGF, EGFR, epiregulin, heparin-binding EGF
(HB-EGF), transforming growth factor (TGF)-a, tenascin C,
VEGF-A, fibroblast growth factor (FGF)-basic, platelet-derived
growth factor-BB, and placental growth factor. Enzyme-linked
immunosorbent assay (ELISA) was performed for heregulin
Table 1. Baseline patient characteristics
Characteristics
FOLFIRI plus
panitumumab
(n = 59)
FOLFIRI plus
bevacizumab
(n = 58)
n % n %
Age, years
Median, range 62 31–82 64 26–78
Age, years
<65 34 57.6 29 50.0
65 or more 25 42.4 29 50.0
Gender
Male 34 57.6 39 67.2
Female 25 42.4 19 32.8
ECOG PS
0 47 79.7 43 74.1
1 12 20.3 15 25.9
K€ohne index
Low 23 39.0 25 43.1
Intermediate 14 23.7 13 22.4
High 22 37.3 20 34.5
Prior surgery
Yes 49 83.1 47 81.0
Prior adjuvant treatment
Yes 16 27.1 15 25.9
Prior first-line treatment
FOLFOX + bevacizumab 45 76.3 45 77.6
CapeOX + bevacizumab 14 23.7 12 20.7
SOX + bevacizumab 0 0 1 1.7
Duration of first-line
6 months or more 50 84.7 49 84.5
Measurable lesion
Present 52 88.1 53 91.4
Metastatic sites
Liver 35 59.3 39 67.2
Lung 31 52.5 28 48.3
Lymph node 24 40.7 21 36.2
No. of metastatic sites
1 22 37.3 20 34.5
2 or more 37 62.7 38 65.5
CapeOX, capecitabine plus oxaliplatin; ECOG PS, Eastern Cooperative
Oncology Group performance status; FOLFIRI, fluorouracil, leucovorin,
and irinotecan; FOLFOX, combination of fluorouracil, leucovorin, and
oxaliplatin; SOX, S1 plus oxaliplatin.
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and HGF using a commercially available sandwich ELISA kit
(DuoSet ELISA development system for human HRG1-b1 and
Quantikine Human HGF Immunoassay; R&D Systems, Min-
neapolis, MN, USA). Expression of extracellular domain of
HER2 was measured by chemiluminescent immunoassay (Sie-
mens Healthcare Diagnostics, Erlangen, Germany). A bead-
based flow cytometric assay using a commercially available
WideScreen Human Cancer Panel 2 kit (Merck, Kenilworth,
NJ, USA) was performed for the remaining biomarkers.
Statistical analysis. The primary endpoint of this study was
OS, which was estimated from the date of trial entry to the
date of death from any cause or censored at the date of last
follow-up. Secondary endpoints included PFS, objective
response rate (ORR), safety, and biomarker research. PFS was
measured from the date of entry into the trial to the time when
progression or death without evidence of progression occurred.
This study was initially designed as a randomized, phase II
trial to evaluate the superiority of FOLFIRI plus bevacizumab
over FOLFIRI plus panitumumab by log-rank test. However,
based on the results of other randomized studies which were
reported after initiation of this study,(5–11) the main objective
of the study was changed to the estimation of hazard ratio
(HR) between the two arms. As such, a revised decision rule
regarding the primary endpoint was determined that the two
arms had similar efficacy for OS when the point estimate of
HR fell in between 0.80 and 1.25. Ensuring 70% or greater
probability that the observed HR was between 0.80 and 1.25
when an expected HR was 1.0 required a total of 86 deaths;
accordingly this trial included a total of 120 patients with 60
subjects per arm. The study protocol was amended on 14th
October 2013.
For biomarker analyses of serum proteins, the predictive and
prognostic values were assessed by dichotomizing at the med-
ian value (i.e., greater than the median denoted high expres-
sion levels and below or equal to the median denoted low
expression levels). In the biomarker analyses, a P-value of
< 0.1 was considered as a possible treatment-by-marker inter-
action. All statistical analyses were performed using SAS v.
9.3 (SAS Institute; Cary, NC, USA), and two-sided P-values
were reported.
Results
Patient population. Between April 2011 and February 2014,
a total of 121 patients were enrolled, all of whom received
allocated treatment (Fig. S1). Two patients in each treatment
arm were excluded from full analysis set (FAS) due to ineligi-
bility; therefore, the FAS included 59 patients in the FOLFIRI
plus panitumumab arm and 58 patients in the FOLFIRI plus
bevacizumab arm. Patients and disease characteristics were
Fig. 1. Kaplan–Meier plots of (a) overall survival
and (b) progression-free survival in the full analysis
set cohort. Bmab, bevacizumab; CI, confidence
interval; HR, hazard ratio; Pmab, panitumumab.
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well balanced between the two arms (Table 1). The cutoff date
for analysis was August 2015, resulting in a median follow-up
time of 15.4 months in FOLFIRI plus panitumumab arm and
13.4 months in FOLFIRI plus bevacizumab arm. The median
treatment cycle was 8 in FOLFIRI plus panitumumab and 10
in FOLFIRI plus bevacizumab. One patient receiving FOLFIRI
plus panitumumab continued protocol treatment at the data
cut-off. The most common reason for treatment discontinuation
was disease progression in 62.7% of FOLFIRI plus panitu-
mumab and in 72.4% of FOLFIRI plus bevacizumab followed
by adverse events.
Efficacy. At the time of analysis, all FAS patients were eval-
uated for efficacy, and 88 patients (75.2%) died. As the pri-
mary analysis, estimating HR of OS between the two arms
provided HR of 1.16 [95% confidence interval (CI), 0.76–1.77;
Fig. 1a], concluding that the arms showed the similar efficacy
based on the decision rule. A median OS was 16.2 months in
the FOLFIRI plus panitumumab arm and 13.4 months in the
FOLFIRI plus bevacizumab arm. The median PFS was
6.0 months in the FOLFIRI plus panitumumab arm and
5.9 months in the FOLFIRI plus bevacizumab arm (HR, 1.14;
95% CI, 0.78–1.66; Fig. 1b). The ORR in patients with mea-
surable disease was 46.2% in FOLFIRI plus panitumumab arm
and 5.7% in FOLFIRI plus bevacizumab (Fisher’s exact test,
P < 0.001; Table S1). Results from the Cox proportional haz-
ards analysis of OS or PFS according to baseline clinicopatho-
logical factors showed possible interactions between history of
previous surgery and treatment outcome in OS, while age and
duration of first-line chemotherapy showed interaction in PFS
(Tables S2 and S3). No other significant interaction was
observed in subgroup analyses.
Adverse events. Among the 121 patients who received allo-
cated treatment, 54 patients (88.5%) in the FOLFIRI plus pani-
tumumab arm and 40 patients (66.7%) in the FOLFIRI plus
bevacizumab arm experienced AEs with worst grades of 3 or
worse (Table 2, P = 0.004). Grade 3 or worse acneiform rash,
stomatitis, and hypomagnesemia were more frequent (>10%)
in the FOLFIRI plus panitumumab, whereas leucopenia was
more frequent in FOLFIRI plus bevacizumab. No treatment-
related deaths occurred.
Subsequent treatments. The subsequent chemotherapy was
administrated in 45 patients (76.3%) in the FOLFIRI plus pani-
tumumab arm and in 46 patients (79.3%) in the FOLFIRI plus
bevacizumab arm after the protocol-specified treatment. Anti-
EGFR monoclonal antibody was used in 72.4% of the patients
in FOLFIRI plus bevacizumab arm and 39.0% of those in
FOLFIRI plus panitumumab arm (Table S4).
Efficacy and mutation status of KRAS, NRAS and BRAF muta-
tions in serum. Among the 117 patients in FAS cohort, consent
for biomarker research was obtained from 109 patients
(93.2%; FOLFIRI plus panitumumab arm, 54 patients; FOL-
FIRI plus bevacizumab arm, 55 patients). Patient characteris-
tics in biomarker population were not significantly different
between the two arms (Fig. S1 and Table S5). Efficacy results
were also consistent with the FAS results (the median OS,
16.2 months in FOLFIRI plus panitumumab vs 13.4 months in
FOLFIRI plus bevacizumab; HR, 1.16; 95% CI, 0.75–1.80).
Success rate of mutation analysis was 100%. Any RAS
(n = 14, 12.8%) or BRAF mutations (n = 5, 4.6%) in ctDNA
were identified in a total of 19 patients (17.4%; Table S6) as
mutually exclusive manner. Patients with any RAS or BRAF
mutation showed worse OS in FOLFIRI plus panitumumab
arm than in FOLFIRI plus bevacizumab arm (median 5.4 vs
8.2 months; HR, 0.42). On the other hand, a trend toward
better OS was observed in patients who were WT for all
examined genes in FOLFIRI plus panitumumab arm than those
in FOLFIRI plus bevacizumab arm (median 18.9 vs
16.1 months; HR 1.21), resulting in significant interaction (P
for interaction = 0.026; Fig. 2a). A possible interaction
between oncogenic mutations and treatment was also observed
for PFS (P = 0.054; Fig. S2A). These observations were con-
sistent after adjustment for stratification variables. For all WT
patients, the ORRs were 52.5% in FOLFIRI plus panitumumab
and 2.6% in FOLFIRI plus bevacizumab (P < 0.001), whereas
it was 0% in FOLFIRI plus panitumumab and 18.2% in FOL-
FIRI plus bevacizumab (P < 0.01) among those with any RAS
or BRAF mutations.
Efficacy and serum protein levels. No significant differences
in serum protein levels were observed between the two arms
(Table S7). Panitumumab led to a better OS than FOLFIRI
plus bevacizumab in patients with low serum VEGF-A level
(median 22.4 vs 13.2 months; HR, 1.92), whereas FOLFIRI
plus bevacizumab showed better OS among those with high
serum VEGF-A level (median 13.7 vs 10.7 months; HR,
0.67), resulting in significant interaction (P for interac-
tion = 0.016; Fig. 2b). These results were consistent when we
limited our analysis to all patients with WT RAS or BRAF
(HR, 2.29 with low serum VEGF-A; HR, 0.64 with high
serum VEGF-A; P for interaction = 0.014) or after adjust-
ment for stratification variables. Although no significant inter-
action between serum VEGF-A level and PFS was observed
(Fig. S2b), the ORR was numerically higher in those patients
with low VEGF-A than those with high VEGF-A in FOLFIRI
plus panitumumab arm (52.0% vs 36.4%) and in FOLFIRI
Table 2. Grade 3 and 4 adverse events
Adverse event
FOLFIRI plus
panitumumab
(n = 61)
FOLFIRI plus
bevacizumab
(n = 60)
≥Grade 3 ≥Grade 3
n % n %
Any adverse events 54 88.5 40 66.7
Neutropenia 30 49.2 28 46.7
Stomatitis 13 21.3 4 6.7
Leucopenia 11 18.0 17 28.3
Acneiform rash 10 16.4 0 0.0
Hypomagnesemia 7 11.5 0 0.0
Anorexia 6 9.8 7 11.7
Proteinuria 6 9.8 2 3.3
Non-neutropenic infection 5 8.2 3 5.0
Dry skin 5 8.2 0 0.0
Paronychia 4 6.6 0 0.0
Thromboembolic events 4 6.6 0 0.0
Anemia 3 4.9 7 11.7
Diarrhea 3 4.9 4 6.7
Nausea 2 3.3 3 5.0
Vomiting 2 3.3 3 5.0
Febrile neutropenia 2 3.3 3 5.0
Fatigue 1 1.6 5 8.3
Thrombocytopenia 1 1.6 3 5.0
Any bleeding 1 1.6 2 3.3
Pneumonitis 1 1.6 1 1.7
Gastrointestinal perforation 0 0.0 1 1.7
FOLFIRI, fluorouracil, leucovorin, and irinotecan.
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on behalf of Japanese Cancer Association.
Cancer Sci | December 2016 | vol. 107 | no. 12 | 1846
Original Article
FOLFIRI plus either panitumumab or bevacizumab www.wileyonlinelibrary.com/journal/cas
plus bevacizumab arm (9.1% and 3.6%). No other biomarkers
were associated with predictive value on treatment outcomes
(Figs 3 and S3).
Discussion
In this randomized study that compared FOLFIRI plus panitu-
mumab with FOLFIRI plus bevacizumab as second-line
chemotherapy in patients with WT KRAS exon 2 mCRC,
similar OS and PFS were observed between the two
treatments, whereas ORR was higher with panitumumab.
These results were in line with a previous study in a similar
setting.(11)
Importantly, this study showed that patients with minor RAS
and BRAF mutations, detected in ctDNA from 12.8% and
4.6% of mCRC patients with wild type of KRAS exon 2 in
tumor tissue at the diagnosis, showed worse prognosis in FOL-
FIRI plus panitumumab. These were similar to the results of
recent studies indicating that extended mutations in RAS genes
and BRAF mutation using archival tumor tissue were negative
predictive factors for anti-EGFR therapy.(6–8) The incidences
of RAS mutations other than exon 2 and 3, and BRAF mutation
were consistent with those obtained from tumor tissues.(6–8)
Although concordance between ctDNA and tumor tissues was
not evaluated in this study, it is suggested that gene status
detected in ctDNA could reflect the tumor biology. Previous
studies indicated that mutational status changed during treat-
ment especially with anti-EGFR therapy.(12,13) Thus, using
ctDNA as non-invasive procedure to determine patient status
immediately just before treatment might be alternative
approach in near future.
Fifteen serum proteins, including VEGF-A, were also evalu-
ated in this study. Of note, the FOLFIRI plus bevacizumab
arm was associated with favorable OS in high serum VEGF-A
subgroup, whereas the FOLFIRI plus panitumumab arm
showed better OS in low serum VEGF-A subgroup. These
findings suggested that sustained activation of VEGF pathway
might predict the benefit of bevacizumab continuation as sug-
gested in previous phase 2 study.(18) However, a correlation
between VEGF expression and treatment outcome with beva-
cizumab was arguable in other studies.(17,22) Therefore, valida-
tion studies are necessary to conclusively determine whether
VEGF-A can be used to optimize bevacizumab or anti-EGFR
therapy.(23)
Fig. 2. Kaplan–Meier plots of overall survival
according to RAS and BRAF mutation status (a) and
according to serum VEGF-A level (b). Bmab,
bevacizumab; CI, confidence interval; HR, hazard
ratio; Pmab, panitumumab. WT, RAS or BRAF wild
type; MT, RAS or BRAF mutant. sVEGF-A, serum
vascular endothelial growth factor-A.
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Several studies reported that the mRNA levels of EGFR
ligands such as amphiregulin and epiregulin in tumor tissue
predicted the efficacy of anti-EGFR therapy.(15,24,25) How-
ever, in this study, circulating protein levels of none of the
EGFR ligands showed significant interaction with treatment
efficacy. While upregulation of bypass signaling pathways,
such as HER2, HER3, and HGF-cMET axes, were reported
to associate with resistance to anti-EGFR therapy.(16,26) How-
ever, our study showed that the levels of circulating
heregulin, extracellular domain of HER2, or HGF did not
significantly correlate with resistance to panitumumab ther-
apy. One possible reason for these discrepancies is that cir-
culating ligand levels might not reflect ligand levels in
tumor.(15)
This study has several limitations. First, the number of
patients in each treatment arm was relatively small. In addi-
tion, we had to set the cut-off values of biomarkers at median
because the sample size was too small to explore several cut-
Category N
All 109
RAS/BRAF status Wild 90
RAS mutant 14
BRAF mutant 5
RAS/BRAF status Wild 90
Any  mutant 19
Heregulin ҅ Median 83
> Median 26
HGF ҅ Median 54
> Median 55
HER2 ҅ Median 56
> Median 53
Amphiregulin ҅ Median 55
> Median 54
Betacellulin ҅ Median 56
> Median 53
EGF ҅ Median 55
> Median 54
EGFR ҅ Median 56
> Median 53
Epiregulin ҅ Median 57
> Median 52
HB-EGF ҅ Median 56
> Median 53
TGF-α ҅ Median 56
> Median 53
Tenascin C ҅ Median 56
> Median 53
VEGF-A ҅ Median 54
> Median 55
FGF-basic ҅ Median 56
> Median 53
PDGF-BB ҅ Median 32
> Median 77
PIGF ҅ Median 57
> Median 52
0.1 Favors Bmab Favors Pmab1
HR 95% CI P
1.17 0.75 1.80 interaction
1.21 0.74 1.99 0.08
0.37 0.11 1.20
0.34 0.03 3.85
1.21 0.74 1.99 0.026
0.41 0.15 1.12
1.08 0.66 1.76 0.47
1.46 0.54 3.92
1.07 0.56 2.03 0.88
1.12 0.61 2.05
1.05 0.57 1.92 0.56
1.38 0.73 2.61
1.36 0.69 2.65 0.72
1.01 0.62 1.95
1.27 0.69 2.34 0.70
1.06 0.57 1.98
1.33 0.68 2.58 0.52
0.97 0.54 1.73
1.45 0.8 2.64 0.28
0.93 0.49 1.78
1.48 0.79 2.77 0.30
0.92 0.5 1.69
1.77 0.88 3.53 0.13
0.88 0.49 1.60
1.58 0.84 2.99 0.18
0.87 0.47 1.6
1.35 0.71 2.56 0.38
0.90 0.50 1.64
1.92 0.98 3.76 0.016
0.67 0.37 1.21
1.49 0.80 2.77 0.27
0.90 0.48 1.69
1.91 0.73 4.95 0.36
1.05 0.63 1.74
1.19 0.63 2.24 0.98
1.14 0.63 2.09
Fig. 3. Comparison of overall survival among patient subgroups according to biomarkers. Patient’s number of each subgroup was not in
half by median value of heregulin or PDGF-BB because not a few patients were associated with undetectable value or maximum value.
CI, confidence interval; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; FGF-basic, fibroblast growth factor-basic;
HB-EGF, heparin-binding EGF; HER2, human epidermal growth factor receptor type 2; HGF, hepatocyte growth factor; HR, hazard ratio;
PDGF-BB, platelet-derived growth factor-BB; PIGF, placental growth factor; TGF-a, transforming growth factor-a; VEGF-A, vascular endothelial
growth factor-A.
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off values. Thus, larger studies are necessary to confirm and
identify optimal cut-off levels. Second, we did not evaluate
biomarkers in tumor tissue. Matched analysis of serum and
tumor tissue should be included in future studies to evaluate
these concordance and predictive values. Because the transla-
tional research is exploratory, statistical correction for multi-
plicity was not performed. Third, although this study showed
higher ORR in FOLFIRI plus panitumumab than FOLFIRI
plus bevacizumab, ORR was not conformed by independent
radiological reviews.
In conclusion, second-line FOLFIRI plus panitumumab and
FOLFIRI plus bevacizumab showed a similar efficacy in
patients with WT KRAS exon 2 mCRC. Additionally, RAS and
BRAF mutation in ctDNA could identify could be a negative
predictive marker for panitumumab. Finally, serum VEGF-A
might be a candidate biomarker for optimizing anti-EGFR
therapy or bevacizumab.
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